公开(公告)号：US20250092042A1

公开(公告)日：2025-03-20

申请号：US18924066

申请日：2024-10-23

Applicant: NOVARTIS AG

Inventor： Mallesh BUSHABOINA ,  Xin CHEN ,  Atwood Kim CHEUNG ,  Andrew James CULSHAW ,  Timothy Brian HURLEY ,  Nancy LABBE-GIGUERE ,  Wolfgang MILTZ ,  David ORAIN ,  Tajesh PATEL ,  Srinivasan RAJAGOPALAN ,  Till ROEHN ,  David Andrew SANDHAM ,  Gebhard THOMA ,  Ritesh Bhanudasji TICHKULE ,  Rudolf WÄLCHLI

IPC: C07D471/10 ,  A61K45/06 ,  C07D519/00

Abstract: The present invention provides a method for manufacturing a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 R2, R4 and X1 are defined herein.

公开(公告)号：US20240043425A1

公开(公告)日：2024-02-08

申请号：US18319585

申请日：2023-05-18

Applicant: NOVARTIS AG

Inventor： Mallesh BUSHABOINA ,  Xin CHEN ,  Atwood Kim CHEUNG ,  Andrew James CULSHAW ,  Timothy Brian HURLEY ,  Nancy LABBE-GIGUERE ,  Wolfgang MILTZ ,  David ORAIN ,  Tajesh PATEL ,  Srinivasan RAJAGOPALAN ,  Till ROEHN ,  David Andrew SANDHAM ,  Gebhard THOMA ,  Ritesh Bhanudasji TICHKULE ,  Rudolf WÄLCHLI

IPC: C07D471/10 ,  A61K45/06 ,  C07D519/00

CPC classification number: C07D471/10 ,  C07D519/00 ,  A61K45/06

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;






wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20140315932A1

公开(公告)日：2014-10-23

申请号：US14322165

申请日：2014-07-02

Applicant: NOVARTIS AG

Inventor： Timothy John RITCHIE ,  Andrew James CULSHAW ,  Christopher Thomas BRAIN ,  Edward Karol DZIADULEWICZ ,  Terance William HART

IPC: C07D401/04 ,  C07D239/91

CPC classification number: C07D401/04 ,  C07D239/91

Abstract: The present specification relates to the use of a quinazolinone compound of the formula (I) wherein R1, R2, R3, R4, R5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form.

Abstract translation: 本说明书涉及式（I）的喹唑啉酮化合物的用途，其中R 1，R 2，R 3，R 4，R 5和m如说明书和权利要求中所定义，为游离形式或盐形式， 在可能的情况下，以酸加成盐形式。